Table 1.
Cohort | Location | Ethnicity | Mean age years (SD) | n | Gender ratio male/female | Iron status marker/erythrocyte trait studied | Confounders considered in association analyses | References |
---|---|---|---|---|---|---|---|---|
– | China | Han (East) | 62.2 (7.7) | 1,141 | 0/100 | Hb, SI, SF, sTfRN, FEP, TIBC | Age | An et al. (2012) |
– | China | Han (North) | 58.2 (7.5) | 354 | 0/100 | Hb, SI, SF, sTfRN, FEP, TIBC | ||
– | China | Zhuang | 59.4 (7.9) | 630 | 0/100 | Hb, SI, SF, sTfRN, FEP, TIBC | ||
Health professional follow-up study (HPFS) and Nurses health study (NHS) | USA | Caucasian | 43.3 (6.7) | 2,422 | – | Ferritin, TfR, TRFN | None | He et al. (2012) |
KORA F3, KORA F4, Micors, InCHIANTI, Croat-Vis | Europe | Caucasian | 58.9 (12.8) | ~6,600 | – | sTfR, SI, TRFN, TRFN saturation | Age, sex | Oexle et al. (2011) |
– | China | Han | 58.3(5.9) | 1,574 | 45.2/45.8 | Hb, PF | Age, sex, dietary iron and BMI | Gan et al. (2012) |
– | USA | Mixed | 56.5(13.5) | 48 | 0/100 | Hb, SI, SF, MCV, TIBC | Age, presence or absence of pica | Lee (2009) |
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium | Europe | Caucasian | 58.5 (8.3) | 24,731 | 43/57 | Hb, Hct, MCH, MCHC, MCV, Erythrocyte count | None | Ganesh et al. (2009) |
Haematology genetics (HAEMGEN) study | Italy | Caucasian | – | 9,456 | – | Hb, Hct, MCH, MCHC, MCV, Erythrocyte count | None | Ganesh et al. (2009) |
InCHIANTI | USA | Caucasian | 68.3 (15.5) | 1,206 | 44/56 | SI, SF, Hb, Hct, MCV, RBC count, RBC width, platelets | Age and gender | Tanaka et al. (2010) |
Women’s Healthy Aging Study (WHAS) I | USA | Caucasian | 78.3 (8.0) | 375 | 0/100 | SI, SF, Hb, Hct, MCV, RBC count, RBC width, platelets | None | Tanaka et al. (2010) |
WHAS II | USA | Caucasian | 74 (2.7) | 194 | 0/100 | SI, SF, Hb, Hct, MCV, RBC count, RBC width, platelets | None | Tanaka et al. (2010) |
InCHIANTI, BLSA, SardiNIA stage 2 | Italy and USA | Caucasian | 59.5 (15.8) | 3,200 | 46/54 | Fe, TRFN, Ferritin, sTfR | Sex, age | Pichler et al. (2011) |
– | Spain | Caucasian | 24.3 (4.8) | 270 | 0/100 | SI, SF, Hb, Hct, MCV, RBC count, TRFN, Transferrin saturation, TIBC | None | Blanco-Rojo et al. (2011) |
Australian Twin families | Australia | Caucasian | Adolescents | ~2,512 | 40/60 | Fe, TRFN, Transferrin saturation, Hb, MCV | Sex, age, sex * age | Benyamin et al. (2009) |
Nijmegen biomedical study (NBS) | NL | Caucasian | – | 1,832 | – | Fe, TRFN, Transferrin saturation, Hb, MCV | None | Benyamin et al. (2009) |
London Life Sciences Population (LOLLIPOP) | UK | Caucasian | 54.5 (9.8) | 1,599 | 87.3/12.7 | Hb, RBC, MCV, MCH, MCHC | None | Chambers et al. (2009) |
LOLLIPOP | UK | Indian Asians | 53.6 (10.8) | 9,685 | 88.8/12.2 | Hb, RBC, MCV, MCH, MCHC | None | Chambers et al. (2009) |
Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk (SAPHIR) | Austria | Caucasian | Range Male 39–66 years Females 39–67 years |
1,726 | 63/37 | Hb, RBC count, SI | Age and gender | Kloss-Brandstatter et al. (2012) |
ValBorbera (VB) study | Italy | Caucasian | 55.4 (17.8) | ~1,650 | 44/56 | Hb, Hct, MCV, MCH, MCHC, SI, TRFN, ferritin, TRFN saturation | None | Traglia et al. (2011) |
Hemochromatosis and Iron Overload Screening (HEIRSa) study | USA | Caucasian | 60.1 (10.4) | 1,084 | 24/76 | SI, UIBC, SF, sTfR, TIBC | Age, sex, ln(CEA), ln(CRP), ln(GGT), C282Y/H63D | McLaren et al. (2012) |
HEIRSa | USA | African-American | 57.5 (12.4) | 221 | 36/64 | SI, UIBC, SF, sTfR, TIBC | ln(CRP), ln(GGT), CagA | McLaren et al. (2012) |
HEIRSa | USA | Hispanic | 56.3 (10.1) | 239 | 25/75 | SI, UIBC, SF, sTfR, TIBC | ln(CEA) | McLaren et al. (2012) |
HEIRSa | USA | Asian | 55.7 (10.9) | 153 | 36/64 | SI, UIBC, SF, sTfR, TIBC | ln(GGT) | McLaren et al. (2012) |
Ethnicities with similar vowels next to them were analysed and compared in the same study
C282Y/H63D genotype, CagA strain infection status (infected vs non-infected)
ln natural log transformation, CEA carcinoembryonic antigen, CRP c-reactive protein , GGT gamma-glutamyltransferase, HFE gene, Hb Haemoglobin, SI serum iron, SF serum ferritin, PF plasma ferritin, TRFN transferrin, sTfRN serum transferrin, sTfR serum transferrin receptor, FEP free erythrocyte porphyrins, TIBC total iron-binding capacity, UIBC unsaturated iron-binding capacity, Hct hematocrit, MCH mean corpuscular haemoglobin, MCHC mean corpuscular haemoglobin concentration, MCV mean corpuscular volume, RBC red blood cell
aAdjustments considered in association testing with serum ferritin
– Information not available